Oligonucleotides are short, synthetic strands of DNA or RNA engineered to treat specific genetic conditions by targeting the messenger RNA (mRNA) and altering protein production. This offers new treatment approaches for genetic disorders and diseases which are considered untreatable.
These molecules interfere with gene expression by either blocking protein production or triggering mRNA degradation providing precise, targeted therapeutic intervention.
Oligonucleotides are synthesized using solid phase chemistry through repetitive cycles of deprotection, coupling, oxidation and capping. This enables the production of precise therapeutic sequences at a commercial scale.
We are committed to the research and development of oligonucleotide therapeutics for rare and orphan diseases. Our core team consists of interdisciplinary scientific professionals with analytical and regulatory expertise. We are striving to address the evolving needs of the oligonucleotide drug landscape.
